-
Study aim
-
The effect of curcumin on the incidence of contrast-induced nephropathy
-
Design
-
This is a triple blinded randomized controlled clinical trial with a parallel group design of 454 patients, in which a random number table was used for randomization.
-
Settings and conduct
-
Patients include all subjects who receive IV. Contrast agent (except the candidate for renal artery angiography) and refer to Velayat, Imam Reza and Ghaem Hospitals and the physician's office. All volunteers, care providers and statistician are blinded after assignment to intervention. So that, the supplements containers were coded as A and B by a non-researcher person and remained confidential until data analysis. The placebos are similar to the supplements regarding the weight and color.
-
Participants/Inclusion and exclusion criteria
-
Hepatic failure, Biliary obstruction, End-stage renal insufficiency, acute renal insufficiency, A history of reaction to contrast media, Taking potentially nephrotoxic medicines, Pulmonary oedema, Gastrointestinal disorders, Multiple myeloma, Exposure to contrast media within 7 days before the procedure, Pregnancy, Taking N-acetyl cysteine, teofiline, dopamine, fenoldopam, manitol, and NaHCO3 within 48 h before coronary angiography.
-
Intervention groups
-
The drug group (n = 227), will receive the curcumin and the control group (n = 227), will take the placebo of the same shape, weight and color with the drug every 8 hours at a dose of 500 mg, from two days before the injection of I.V. contrast agent to 48 hours after the intervention.
-
Main outcome variables
-
Increased serum creatinine levels after 48 hours of contrast agent injection